bluebird bio (NASDAQ: BLUE) recently received a number of ratings updates from brokerages and research firms:

  • 11/3/2017 – bluebird bio had its price target raised by analysts at SunTrust Banks, Inc. from $108.00 to $163.00. They now have a “buy” rating on the stock.
  • 11/3/2017 – bluebird bio had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $130.00 price target on the stock.
  • 11/3/2017 – bluebird bio was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating.
  • 11/2/2017 – bluebird bio was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $177.00 price target on the stock.
  • 11/2/2017 – bluebird bio had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $170.00 price target on the stock.
  • 11/2/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $174.00 price target on the stock, up previously from $135.00.
  • 11/2/2017 – bluebird bio had its price target raised by analysts at Barclays PLC from $151.00 to $162.00. They now have an “overweight” rating on the stock.
  • 11/1/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $162.00 price target on the stock, up previously from $145.00.
  • 11/1/2017 – bluebird bio had its “sell” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $58.00 price target on the stock, up previously from $39.00. They wrote, “Directionally Improving. From the ASH abstracts we have an early glimpse at the modified drug manufacturing process for SCD. Two patients were treated with the modified drug product having VCNs of 1.4/3.3 and 5.0/2.9, respectively. In patient 1313, VCN dropped in peripheral blood to 0.5 and HbA T87Q was measured at 1.5g/dL by three months. Patient 1312 demonstrated a declining VCN at 2.6 at one month. While the first patient demonstrated HbA T87Q of 1.5g/dL, we note that these concentrations may not reach steady state until nine months following drug product infusion. While an additional eight patients treated with apheresis-derived (previously bone marrow) stem cells have been enrolled by July 21, 2017, we do not expect in vivo clinical data at ASH. bluebird expects to provide an update on its fully enrolled (n=15) Northstar-2 trial in b-thalassemia patients with the non-b0/b0 genotype at ASH.””
  • 10/30/2017 – bluebird bio had its price target raised by analysts at BMO Capital Markets from $134.00 to $162.00. They now have a “buy” rating on the stock.
  • 10/16/2017 – bluebird bio was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $102.00 price target on the stock.
  • 10/11/2017 – bluebird bio had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $126.00 price target on the stock.
  • 10/9/2017 – bluebird bio had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $170.00 price target on the stock, up previously from $100.00.
  • 10/6/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $145.00 price target on the stock, up previously from $120.00.
  • 10/6/2017 – bluebird bio had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $186.00 price target on the stock.
  • 10/2/2017 – bluebird bio was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $105.00 price target on the stock. They wrote, “excitement.” But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm’s Matthew Harrison downgraded Bluebird’s stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to “increase investor confidence” in its sickle cell gene therapy.”Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially,” the analyst explained. “We do not believe the evidence supports current investor optimism that this can be solved by ASH.”
  • 9/30/2017 – bluebird bio had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $120.00 price target on the stock.
  • 9/28/2017 – bluebird bio had its “sell” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $39.00 price target on the stock. They wrote, “bluebird bio announced that the first multiple myeloma patient was dosed with its next-generation CAR-T product candidate bb21217.””

Shares of bluebird bio, Inc. (NASDAQ:BLUE) opened at $144.75 on Tuesday. bluebird bio, Inc. has a 52 week low of $41.25 and a 52 week high of $164.80.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company’s quarterly revenue was up 397.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.07) EPS. sell-side analysts anticipate that bluebird bio, Inc. will post -6.76 earnings per share for the current year.

In other news, Director Daniel Lynch sold 500 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total value of $60,000.00. Following the transaction, the director now owns 3,300 shares in the company, valued at $396,000. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jeffrey T. Walsh sold 1,250 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $95.41, for a total transaction of $119,262.50. Following the completion of the transaction, the insider now owns 28,555 shares in the company, valued at approximately $2,724,432.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 185,518 shares of company stock worth $24,292,373. Insiders own 3.90% of the company’s stock.

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.